The current data indicate that drugs that reduce RAS pro-inflammatory activity (ACEIs and, particularly, ARBs) can be beneficial for the COVID-19 outcome, both by reducing organ (particularly lung) inflammation and by triggering mechanisms (such as ADAM17 inhibition) that counteract a possible increase in viral entry related to the increase in the expression of cell ACE2. Here, ADAM17 is linked to COVID-19.